GSK signed a definitive agreement to acquire Nuvalent for $10.6 billion. The transaction secures a portfolio of next-generation precision cancer therapies and novel kinase inhibitors.
The deal includes two drug candidates for non-small cell lung cancer (NSCLC) currently under FDA review. GSK expects regulatory decisions on these assets later this year.
Management identifies multi-blockbuster potential for both drugs and plans to launch them in 2024 if approved. Truist analysts project combined peak revenue of approximately $3.5 billion for the lead candidates.
The transaction marks the second-largest biopharma deal of the year. The parties expect the acquisition to close in the third quarter of 2026.